患者报告结局指标如何影响银屑病关节炎治疗强化与患者满意度?一项503例患者的横断面研究
ASSIST研究在英国和欧洲纳入503例银屑病关节炎患者,于2021年7月至2022年3月完成PsAID-12问卷并与医生共享结果。36.2%患者治疗发生改变,其中88.8%为治疗强化;PsAID-12评分升高与治疗强化几率增加相关(OR 1.58,P<0.0001),但多数临床医生报告PsAID-12未影响其强化决策,而是支持减量决策。
要点
- 36.2%患者治疗发生改变,其中88.8%为治疗强化。
- PsAID-12评分升高与治疗强化几率增加相关(OR 1.58,P<0.0001)。
- 医生对疾病活动度的评估对治疗强化可能性影响最显著(每增加1分OR 2.68)。
核心结论
- PsAID-12评分与多项疾病严重度指标及治疗强化几率相关,但多数临床医生报告PsAID-12未影响其治疗强化决策。
- 作者认为PsAID评分可用于增加治疗减量决策的信心。
研究设计与样本
- ASSIST研究为横断面研究,在英国和欧洲于2021年7月至2022年3月纳入503例银屑病关节炎患者。
- 患者完成PsAID-12问卷,结果与医生共享,并记录患者特征、疾病活动度、当前治疗、治疗策略、用药变化及患者满意度评分。
主要发现
- 36.2%患者治疗发生改变,其中88.8%为治疗强化。
- 治疗强化患者的PsAID-12平均评分更高;PsAID-12评分升高与治疗强化几率增加相关(OR 1.58,P<0.0001)。
- 多数临床医生报告PsAID-12未影响其治疗强化决策,而是支持治疗减量决策。
- 医生对疾病活动度的评估对治疗强化可能性影响最显著(每增加1分OR 2.68)。
- 未接受生物制剂治疗的患者更可能发生治疗强化;其他与治疗强化相关的因素包括患者特征、医生特征、疾病活动度和疾病影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The AsseSSing Impact in pSoriatic Treatment (ASSIST) study investigated prescribing in routine PsA care and whether the patient-reported outcome-PsA Impact of Disease questionnaire (PsAID-12)-impacted treatment. This study also assessed a range of patient and clinician factors and their relationship to PsAID-12 scoring and treatment modification. METHODS: Patients with PsA were selected across the UK and Europe between July 2021 and March 2022. Patients completed the PsAID questionnaire and the results were shared with their physician. Patient characteristics, disease activity, current treatment methods, treatment strategies, medication changes and patient satisfaction scores were recorded. RESULTS: A total of 503 patients were recruited. Some 36.2% had changes made to treatment, and 88.8% of these had treatment escalation. Overall, the mean PsAID-12 score was higher for patients with treatment escalation; increase in PSAID-12 score is associated with increased odds of treatment escalation (odds ratio 1.58; P < 0.0001). However, most clinicians reported that PsAID-12 did not impact their decision to escalate treatment, instead supporting treatment reduction decisions. Physician's assessment of disease activity had the most statistically significant effect on likelihood of treatment escalation (odds ratio 2.68, per 1-point score increase). Escalation was more likely in patients not treated with biologic therapies. Additional factors associated with treatment escalation included: patient characteristics, physician characteristics, disease activity and disease impact. CONCLUSION: This study highlights multiple factors impacting treatment decision-making for individuals with PsA. PsAID-12 scoring correlates with multiple measures of disease severity and odds of treatment escalation. However, most clinicians reported that the PsAID-12 did not influence treatment escalation decisions. Psoriatic Arthritis Impact of Disease (PsAID) scoring could be used to increase confidence in treatment de-escalation.
引用
- Coyle C, Watson L, Whately-Smith C, et al. How do patient-reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients. Rheumatology (Oxford). 2025. PMID: 38191998. doi:10.1093/rheumatology/kead679
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。